Academic Journal
View in EDS

Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.

Bibliographic Details
Title: Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.
Authors: Akakura, Koichiro, Uemura, Hiroji, Kawakami, Satoru, Yokomizo, Akira, Nakamura, Motonobu, Nishimura, Kazuo, Komori, Tetsushi, Ledesma, Dianne Athene
Source: Future Oncology; Apr2024, Vol. 20 Issue 12, p781-798, 18p
Abstract: Aim: We aimed to determine Japanese metastatic castration resistant prostate cancer (CRPC) patients' Ra-223 treatment experience. Patients & methods: Patients answered the Cancer Therapy Satisfaction Questionnaire (CTSQ domains: Satisfaction with Therapy [SWT], Expectations of Therapy [ET], Feelings about Side Effects [FSE]), the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) and the FACT-Bone Pain (FACT-BP) Questionnaire at baseline, during (vists 3 and 5) and after treatment (end of observation; EOO). Results: Data from 72 patients were included. Baseline median CTSQ scores SWT: 66.1 (IQR19.7), ET: 75.0 (IQR45), and FSE 68.8 (IQR 34.4) were unchanged during vists 3 and 5, but the SWT (-3.57 [IQR17.9]) and ET (-5.0 [IQR30]) decreased while FSE was unchanged (0.0 [IQR31.25]) at EOO. The median MAX-PC (18.0 [IQR 49]) score was unchanged (0.0, IQR 6) while the median FACT BP (54.0 [IQR13]) score decreased by -1.0 (IQR 8) at EOO. Conclusion: Japanese metastatic castration resistant prostate cancer patients' experience is stable during Ra-223 treatment. We wanted to know the treatment experience with Radium-223 (Ra-223) among Japanese prostate cancer patients. Ra-223 is a radioactive molecule used for the treatment of metastatic castration resistant prostate cancer. We asked patients to answer different questionnaires on treatment satisfaction, anxiety and quality of life before, during, and after treatment with Ra-223. Based on the patients' answers to our questionnaires, treatment satisfaction, anxiety and quality of life remain stable while the patients undergo treatment with Ra-223, but in some aspects may decline after treatment. The results mean that patients' experience during Ra-223 treatment is stable but patients should share any concerns they have about their treatment with their doctors. A study on Japanese metastatic castration resistant prostate cancer patients who receive Radium-223 therapy showed that treatment satisfaction, anxiety and health-related quality of life remain stable among patients while undergoing Ra-223 treatment. [ABSTRACT FROM AUTHOR]
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=14796694&ISBN=&volume=20&issue=12&date=20240410&spage=781&pages=781-798&title=Future Oncology&atitle=Metastatic%20castration%20resistant%20prostate%20cancer%20patients%27%20experience%20with%20Radium-223%20treatment%20in%20Japan.&aulast=Akakura%2C%20Koichiro&id=DOI:10.2217/fon-2023-0870
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: edb
DbLabel: Complementary Index
An: 176212413
RelevancyScore: 1007
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1007.04071044922
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Akakura%2C+Koichiro%22">Akakura, Koichiro</searchLink><br /><searchLink fieldCode="AR" term="%22Uemura%2C+Hiroji%22">Uemura, Hiroji</searchLink><br /><searchLink fieldCode="AR" term="%22Kawakami%2C+Satoru%22">Kawakami, Satoru</searchLink><br /><searchLink fieldCode="AR" term="%22Yokomizo%2C+Akira%22">Yokomizo, Akira</searchLink><br /><searchLink fieldCode="AR" term="%22Nakamura%2C+Motonobu%22">Nakamura, Motonobu</searchLink><br /><searchLink fieldCode="AR" term="%22Nishimura%2C+Kazuo%22">Nishimura, Kazuo</searchLink><br /><searchLink fieldCode="AR" term="%22Komori%2C+Tetsushi%22">Komori, Tetsushi</searchLink><br /><searchLink fieldCode="AR" term="%22Ledesma%2C+Dianne+Athene%22">Ledesma, Dianne Athene</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Future Oncology; Apr2024, Vol. 20 Issue 12, p781-798, 18p
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aim: We aimed to determine Japanese metastatic castration resistant prostate cancer (CRPC) patients' Ra-223 treatment experience. Patients & methods: Patients answered the Cancer Therapy Satisfaction Questionnaire (CTSQ domains: Satisfaction with Therapy [SWT], Expectations of Therapy [ET], Feelings about Side Effects [FSE]), the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) and the FACT-Bone Pain (FACT-BP) Questionnaire at baseline, during (vists 3 and 5) and after treatment (end of observation; EOO). Results: Data from 72 patients were included. Baseline median CTSQ scores SWT: 66.1 (IQR19.7), ET: 75.0 (IQR45), and FSE 68.8 (IQR 34.4) were unchanged during vists 3 and 5, but the SWT (-3.57 [IQR17.9]) and ET (-5.0 [IQR30]) decreased while FSE was unchanged (0.0 [IQR31.25]) at EOO. The median MAX-PC (18.0 [IQR 49]) score was unchanged (0.0, IQR 6) while the median FACT BP (54.0 [IQR13]) score decreased by -1.0 (IQR 8) at EOO. Conclusion: Japanese metastatic castration resistant prostate cancer patients' experience is stable during Ra-223 treatment. We wanted to know the treatment experience with Radium-223 (Ra-223) among Japanese prostate cancer patients. Ra-223 is a radioactive molecule used for the treatment of metastatic castration resistant prostate cancer. We asked patients to answer different questionnaires on treatment satisfaction, anxiety and quality of life before, during, and after treatment with Ra-223. Based on the patients' answers to our questionnaires, treatment satisfaction, anxiety and quality of life remain stable while the patients undergo treatment with Ra-223, but in some aspects may decline after treatment. The results mean that patients' experience during Ra-223 treatment is stable but patients should share any concerns they have about their treatment with their doctors. A study on Japanese metastatic castration resistant prostate cancer patients who receive Radium-223 therapy showed that treatment satisfaction, anxiety and health-related quality of life remain stable among patients while undergoing Ra-223 treatment. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label:
  Group: Ab
  Data: <i>Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=176212413
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2217/fon-2023-0870
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 18
        StartPage: 781
    Titles:
      – TitleFull: Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Akakura, Koichiro
      – PersonEntity:
          Name:
            NameFull: Uemura, Hiroji
      – PersonEntity:
          Name:
            NameFull: Kawakami, Satoru
      – PersonEntity:
          Name:
            NameFull: Yokomizo, Akira
      – PersonEntity:
          Name:
            NameFull: Nakamura, Motonobu
      – PersonEntity:
          Name:
            NameFull: Nishimura, Kazuo
      – PersonEntity:
          Name:
            NameFull: Komori, Tetsushi
      – PersonEntity:
          Name:
            NameFull: Ledesma, Dianne Athene
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 04
              Text: Apr2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 14796694
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Future Oncology
              Type: main
ResultId 1